Janux Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Janux Therapeutics, Inc. (JANX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-68.99-58.29-63.06-32.67-6.78
Depreciation & Amortization2.061.960.840.110.01
Stock Based Compensation33.0220.0117.206.910.07
Change in Working Capital0.69-6.554.288.840.39
Change in Accounts Receivable0.000.000.008.00-8.00
Change in Accounts Payable1.580.28-0.292.140.01
Change in Other Working Capital0.81-0.912.810.840.38
Other Operating Activities-10.5913.0020.496.921.94
Net Cash from Operating Activities-43.81-50.58-42.92-16.98-4.37
Investing Activities
Capital Expenditures-0.36-1.85-6.45-1.480.00
Purchases of Investments-470.58-39.3464.71-473.630.00
Sales/Maturities of Investments212.92278.00359.10134.150.00
Net Cash from Investing Activities-258.02-41.1958.27-340.960.00
Financing Activities
Common Stock Issued698.2759.550.50204.170.07
Other Financing Activities14.970.000.501.810.00
Net Cash from Financing Activities713.2459.550.50386.5211.52
Summary
Net Change in Cash411.40-32.2215.8428.597.16
Cash at Beginning of Period20.0252.2436.407.810.00
Cash at End of Period431.42-52.4352.2436.400.00
Free Cash Flow-44.17-52.43-49.37-18.46-4.37